John Altin is an Associate Professor who works across the advanced Immunology and Microbial Sciences, and Bioinnovation and Genome Sciences Divisions at TGen. His research interests lie at the intersection of the adaptive immune system, genomics and biotechnology.
John began his research career in the Immunogenomics lab of Chris Goodnow, where he used genome-wide mouse mutagenesis and cellular immunology techniques to reveal new pathways of T cell regulation. After graduating in 2012, he joined Prognosys Biosciences, a start-up biotech company founded by Mark Chee in San Diego where he developed new assays to view T and B lymphocyte responses at high-resolution. In 2017 John joined the faculty at TGen where he has since developed a research program that has attracted > $10M in revenue to study adaptive immune response in a diverse range of settings that include the human Virome, Tuberculosis, SARS-CoV-2, Malaria and Type I Diabetes.
His lab aims to bring advances in genomic technology to the high-dimensional study of the targets of adaptive immunity, ultimately in search of improved preventative, diagnostic, and treatment strategies for infectious diseases, particularly those of global relevance.
Further details about current lab activities may be found at the lab website.View Full Publication Listing
We found 5 results matching most recent news articles for "John Altin"
We found 2 results matching most recent podcasts for "John Altin"